Inspire Medical Systems (NYSE:INSP) Updates FY24 Earnings Guidance

Inspire Medical Systems (NYSE:INSP) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided EPS guidance of $0.10-0.20 for the period, compared to the consensus EPS estimate of ($0.32). The company issued revenue guidance of $783-793 million, compared to the consensus revenue estimate of $782.27 million.

Inspire Medical Systems Stock Performance

Inspire Medical Systems stock traded up $10.95 during mid-day trading on Thursday, reaching $174.36. The stock had a trading volume of 1,454,956 shares, compared to its average volume of 577,797. The firm has a market capitalization of $5.28 billion, a PE ratio of -317.16 and a beta of 1.35. Inspire Medical Systems has a fifty-two week low of $123.27 and a fifty-two week high of $330.00. The stock’s 50-day simple moving average is $215.68 and its 200-day simple moving average is $190.38.

Inspire Medical Systems (NYSE:INSP) last posted its earnings results on Tuesday, May 7th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.29. The company had revenue of $164.01 million during the quarter, compared to the consensus estimate of $161.41 million. Inspire Medical Systems had a negative net margin of 3.39% and a negative return on equity of 3.93%. The firm’s revenue for the quarter was up 28.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.53) earnings per share. On average, research analysts forecast that Inspire Medical Systems will post -0.35 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on INSP. Royal Bank of Canada began coverage on Inspire Medical Systems in a research note on Friday, April 19th. They issued an outperform rating and a $285.00 target price on the stock. Truist Financial restated a buy rating and issued a $280.00 price objective on shares of Inspire Medical Systems in a research note on Wednesday, March 20th. Piper Sandler boosted their price target on shares of Inspire Medical Systems from $250.00 to $255.00 and gave the stock an overweight rating in a report on Wednesday. Morgan Stanley began coverage on shares of Inspire Medical Systems in a research note on Tuesday, March 19th. They set an overweight rating and a $250.00 price target for the company. Finally, KeyCorp initiated coverage on shares of Inspire Medical Systems in a research note on Tuesday, February 6th. They set an overweight rating and a $278.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of Moderate Buy and an average price target of $256.53.

Insiders Place Their Bets

In other news, Director Jerry C. Griffin sold 554 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $198.05, for a total value of $109,719.70. Following the sale, the director now directly owns 9,744 shares of the company’s stock, valued at approximately $1,929,799.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Inspire Medical Systems news, insider Randy Ban sold 3,060 shares of the stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $182.01, for a total value of $556,950.60. Following the transaction, the insider now owns 3,029 shares of the company’s stock, valued at $551,308.29. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Jerry C. Griffin sold 554 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $198.05, for a total transaction of $109,719.70. Following the sale, the director now directly owns 9,744 shares of the company’s stock, valued at $1,929,799.20. The disclosure for this sale can be found here. Insiders sold 76,371 shares of company stock worth $15,664,278 over the last three months. Company insiders own 4.10% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.